Review
Immunology
Jinhai Shen, Hui Hou, Bowen Liang, Xiao Guo, Li Chen, Yong Yang, Yun Wang
Summary: This study evaluated the effect of RAASIs in combination with ICIs on the prognosis of cancer patients. The results showed that the concomitant use of RAASIs and ICIs improved overall survival, especially in patients with urothelial carcinoma and renal cell carcinoma. Therefore, RAASIs can be considered as adjuvant drugs for hypertensive patients receiving ICIs treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
C. H. Chiang, S. S. Wang, Y. C. Chang, C. H. Chiang, C. Y. Chen, Y. J. Chen, X. Y. See, C. Y. Peng, Y. P. Hsia, C. H. Chiang, C. M. Peng
Summary: This study found that the use of RAASi is associated with improved overall survival, progression-free survival, and clinical benefit rates in patients receiving immune checkpoint inhibitors.
Review
Pharmacology & Pharmacy
Persoulla A. Nicolaou
Summary: Sex-related differences in clinical manifestations, risk factors, and treatment drug use in patients with heart failure are significant, particularly in the regulation of the renin-angiotensin-aldosterone system (RAAS). While current evidence suggests potential differences in the efficacy of RAAS drugs between men and women, further research is needed to determine the optimal treatment strategies for both genders.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Seung-Hwa Lee, Jungchan Park, Rae Woong Park, Seo Jeong Shin, Jinseob Kim, Ji Dong Sung, Dae Jung Kim, Kwangmo Yang
Summary: Studies have shown conflicting results on the association between the use of RAAS inhibitors and cancer development. This study compared the incidence of cancer between patients using RAAS inhibitors and other antihypertensive drugs. The findings suggest that the use of RAAS inhibitors may be associated with a lower incidence of cancer.
Article
Cardiac & Cardiovascular Systems
Hye-Jin Park, Ho-Jun Jang, Tae-Hoon Kim, Sung Woo Kwon, Sang-Don Park, Min Gyu Kong, Jon Suh, Pyung Chun Oh, Jeonggeun Moon, Kyounghoon Lee, Woong Chol Kang
Summary: This study compared the efficacy of ACEIs and ARBs in Asian patients with STEMI undergoing PCI and examined the impact of medication adequacy on clinical outcomes. The results showed that ACEIs may be a better choice than ARBs after primary revascularization, but early ACEI dose escalation combined with beta-blocker use may not improve prognosis.
REVIEWS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Oncology
Driss Laghlam, Anis Chaba, Matthias Tarneaud, Julien Charpentier, Jean-Paul Mira, Frederic Pene, Clara Vigneron
Summary: This retrospective study aimed to assess the prognostic impact of renin-angiotensin system blockers (RABs) in critically ill cancer patients. The results showed that the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEis) was associated with improved in-ICU survival and one-year survival. Cellular evidence supports the beneficial impact of RABs on the survival rates of solid tumor patients.
Article
Multidisciplinary Sciences
Susanne Rysz, Jonathan Al-Saadi, Anna Sjostrom, Maria Farm, Francesca Campoccia Jalde, Michael Platten, Helen Eriksson, Margareta Klein, Roberto Vargas-Paris, Sven Nyren, Goran Abdula, Russell Ouellette, Tobias Granberg, Malin Jonsson Fagerlund, Johan Lundberg
Summary: Studies suggest that RAAS imbalance worsens the prognosis in COVID-19 patients, and experiments in pigs show that over-activation of ACE2 and RAAS can lead to a disease state similar to COVID-19 in humans. Imbalanced RAAS state in animals can be ameliorated by angiotensin receptor blockers and low-molecular-weight heparin.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Cho-Han Chiang, Yu-Cheng Chang, Shih-Syuan Wang, Yuan-Jen Chen, Xin Ya See, Chun-Yu Peng, Yuan Ping Hsia, Cho-Hsien Chiang, Cho-Hung Chiang, Cheng-Ming Peng
Summary: This retrospective cohort study investigated the impact of PPAR-gamma-activating ARBs on the survival of patients treated with immune checkpoint inhibitors (ICIs). The results showed that patients who used PPAR-gamma-activating ARBs had longer overall survival and progression-free survival, as well as lower disease progression and overall mortality rates compared to non-PPAR-gamma-ARB users. Patients who received PPAR-gamma-activating ARBs also had a higher clinical benefit rate.
Review
Biochemistry & Molecular Biology
Anastasia Poznyak, Dwaipayan Bharadwaj, Gauri Prasad, Andrey Grechko, Margarita A. Sazonova, Alexander N. Orekhov
Summary: Atherosclerosis has a complex pathogenesis involving inflammation, lipid metabolism alterations, and endothelial injury. The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in the inflammatory response regulation, making it a promising target for atherosclerosis treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Peripheral Vascular Disease
Juntao Yin, Chaoyang Wang, Xiaoyong Song, Xiumin Li, Mingsan Miao
Summary: Based on the available data, ACEI/ARB is not associated with the risk of mortality and disease severity in COVID-19 patients. And ACEI/ARB medications, especially ARB, should not be discontinued for patients with COVID-19.
AMERICAN JOURNAL OF HYPERTENSION
(2022)
Article
Critical Care Medicine
Neha Gupta, Lisa Settle, Brent R. Brown, Donna L. Armaignac, Michael Baram, Nicholas E. Perkins, Margit Kaufman, Roman R. Melamed, Amy B. Christie, Valerie C. Danesh, Joshua L. Denson, Sreekanth R. Cheruku, Karen Boman, Vikas Bansal, Vishakha K. Kumar, Allan J. Walkey, Juan P. Domecq, Rahul Kashyap, Christopher E. Aston
Summary: In hospitalized COVID-19 patients, prior use of a combination of renin-angiotensin-aldosterone system inhibitors (RAASIs) was associated with higher in-hospital mortality compared to the use of RAASIs alone. Compared to ARBs, ACEIs were associated with significantly higher mortality in hospitalized COVID-19 patients.
CRITICAL CARE MEDICINE
(2022)
Article
Physiology
Lale A. A. Ertuglu, Ashley Pitzer Mutchler, Fernando Elijovich, Cheryl L. L. Laffer, Quanhu Sheng, Celestine N. N. Wanjalla, Annet Kirabo
Summary: This study investigated the effects of high salt diet on the expression of RAAS genes in myeloid immune cells and its impact on salt-sensitive hypertension in humans. The results showed that high sodium exposure downregulated the expression of renin in immune cells, but there were no significant changes in the genes of the renin-angiotensin system in response to dietary salt loading and depletion. These findings suggest that acute changes in dietary salt intake do not regulate RAAS expression in myeloid immune cells, unlike the systemic RAAS.
FRONTIERS IN PHYSIOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Agnieszka Dettlaff-Pokora, Julian Swierczynski
Summary: SARS-CoV-2 impairs the renin-angiotensin-aldosterone system by binding the ACE2 enzyme, leading to an increase in angiotensin 2 and a decrease in angiotensin (1-7), potentially worsening damage to the lungs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Ruxin Wang, Haowen Ye, Yongting Zhao, Jinjing Wei, Ying Wang, Xiaofang Zhang, Lihong Wang
Summary: This meta-analysis found that sacubitril/valsartan has a positive effect on glycemic control and the prevention of new-onset diabetes mellitus, especially in patients with heart failure.
Article
Pharmacology & Pharmacy
Fei Qin, Jianling Li, Yong-Fa Dai, Xiao-ge Zhong, Ya-jin Pan
Summary: The study demonstrated that renal denervation reduces levels of RAAS components such as aldosterone and Ang II, leading to lower blood pressure and improved renal function.
CLINICAL AND EXPERIMENTAL HYPERTENSION
(2022)
Article
Engineering, Electrical & Electronic
Anubhav Kumar, Asok De, R. K. Jain
Summary: This study presents a two-element textile antenna with high isolation and polarization diversity, suitable for 5G communications, wearable technology, and biomedical cancer detection applications. The use of flexible material and an orthogonally placed microstrip-feed radiator antenna enables polarization diversity, while high isolation and low correlation are achieved through a defected ground. The antenna demonstrates circular polarization and performs well in terms of impedance bandwidth, isolation, envelope correlation coefficient, and channel capacity loss.
INTERNATIONAL JOURNAL OF MICROWAVE AND WIRELESS TECHNOLOGIES
(2023)
Review
Oncology
Sonia A. Patel, Monique B. Nilsson, Xiuning Le, Tina Cascone, Rakesh K. Jain, John V. V. Heymach
Summary: Angiogenesis is an important mechanism used by solid tumors to recruit blood vessels for growth. Drugs targeting the VEGF/VEGFR pathway have been approved for various solid tumor types, but the survival benefits have been limited. However, these drugs have the potential to reprogram the tumor microenvironment, leading to the approval of combinations with immune checkpoint blockers. Understanding the mechanisms of response and resistance to these drugs is crucial for developing more effective therapeutic approaches.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Nathalie Testart Dardel, Elsa Isenborghs, Massimo Valerio, Olivier Michielin, Niklaus Schaefer
Summary: This case demonstrates an unusual presentation of melanoma metastasis in the right seminal vesicle, detected by F-18-FDG digital PET/CT. Histological analysis confirmed the diagnosis and the patient received stereotactic radiation therapy. The study highlights the excellent performance of state-of-the-art digital PET/CT and emphasizes the importance of a multidisciplinary approach in the treatment and follow-up of melanoma patients.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Oncology
Nisha Gupta, Hiroki Ochiai, Yoshinori Hoshino, Sebastian Klein, Jozef Zustin, Rakesh R. Ramjiawan, Shuji Kitahara, Nir Maimon, Despina Bazou, Sarah Chiang, Sen Li, Daniel H. Schanne, Rakesh. K. Jain, Lance L. Munn, Peigen Huang, Sergey V. Kozin, Dan G. Duda
Summary: Radiotherapy is an important treatment for advanced prostate cancer. Inhibition of the SDF1 alpha/CXCR4 axis, which mediates metastasis and resistance to radiotherapy, may be a potential therapeutic target for prostate cancer patients. Inhibition of CXCR4 with AMD3100 enhances the effect of local radiotherapy and reduces lymph node metastasis. It also promotes the normalization of vasculature and reduces tissue hypoxia in bone metastatic prostate cancer.
Article
Immunology
Balint Dracz, Veronika Mueller, Istvan Takacs, Krisztina Hagymasi, Elek Dinya, Pal Miheller, Attila Szijarto, Klara Werling
Summary: Patients with cirrhosis are at higher risk of hepatic decompensation and death when infected with COVID-19, highlighting the importance of primary vaccination with COVID-19 vaccines. Limited data exists comparing the efficacy of mRNA vaccines to other vaccines in cirrhosis. This retrospective study found that cirrhosis patients receiving mRNA vaccines had better survival rates and lower rates of complications compared to those receiving viral vector or inactivated vaccines. BNT162b2 vaccine showed the highest efficacy in preventing acute hepatic decompensation, COVID-19 infection requiring hospital admission, and in-hospital mortality.
Article
Oncology
Sandro Anchisi, Anita Wolfer, Bettina Bisig, Edoardo Missiglia, Amine Tiab, Ehab Mohamed Kamel, Olivier Michielin, George Coukos, Krisztian Homicsko
Summary: The treatment of BRAFV600E mutant melanoma has been revolutionized by BRAF inhibitors, and BRAF/MEK combination has shown further improvements. BRAF inhibitor use has also been proposed in low-grade ovarian tumors.
CANCER BIOLOGY & THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Jeremy Gungabeesoon, Nicolas A. Gort-Freitas, Mate Kiss, Evangelia Bolli, Marius Messemaker, Marie Siwicki, Mehdi Hicham, Ruben Bill, Peter Koch, Chiara Cianciaruso, Florent Duval, Christina Pfirschke, Michael Mazzola, Solange Peters, Krisztian Homicsko, Christopher Garris, Ralph Weissleder, Allon M. Klein, Mikael J. Pittet
Summary: Neutrophils accumulate in solid tumors and their abundance is associated with poor prognosis. In this study, the role of neutrophils in immunotherapy and tumor control was investigated. The results demonstrate that successful therapies can expand tumor neutrophil numbers and thereby contribute to antitumor effects.
Article
Oncology
Yves Boucher, Jessica M. Posada, Sonu Subudhi, Ashwin S. Kumar, Spencer R. Rosario, Liqun Gu, Heena Kumra, Mari Mino-Kenudson, Nilesh P. Talele, Dan G. Duda, Dai Fukumura, Jennifer Y. Wo, Jeffrey W. Clark, David P. Ryan, Carlos Fernandez-Del Castillo, Theodore S. Hong, Mikael J. Pittet, Rakesh K. Jain
Summary: In this study, we found that adding losartan (LOS) to FOLFIRINOX (FFX) chemotherapy followed by chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC) resulted in a 61% R0 surgical resection rate. By evaluating the effects of neoadjuvant LOS on the tumor microenvironment, we identified potential mechanisms of benefit. The results showed that LOS+FFX+CRT reduced the expression of immunosuppression and pro-invasion genes and was associated with improved overall survival (OS).
CLINICAL CANCER RESEARCH
(2023)
Article
Engineering, Electrical & Electronic
Anubhav Kumar, Asok De, R. K. Jain
Summary: In this paper, a compact two-port antenna design is proposed, featuring an open-ended slot loaded with shorting pins and a T-shaped stub. The antenna radiators, shaped like beaks, enhance bandwidth and electrical length. Dual-operating bands are achieved by the two inverted L-shaped open-ended slots, which create an effective capacitance and inductance. The T-shaped stub improves impedance matching and electrical height to ground, while the combination of the T-shape and open-ended slots provides a dual-band response and up to 8 dB of isolation improvement. Shorting pins connected to the ground exhibit inductive behavior, resulting in isolation improvements of up to 6 dB and 4 dB for the low- and high-frequency bands. The two-port antenna demonstrates over 20 dB of isolation with a mere 2 mm edge-to-edge distance. Operating in the frequency ranges of 4.1 GHz to 4.6 GHz and 5.55 GHz to 6 GHz, the antenna's size of 32 mm x 26.5 mm makes it suitable for 5G and WLAN/ISM applications.
IETE JOURNAL OF RESEARCH
(2023)
Correction
Immunology
Vincenzo Bronte, Mikael J. Pittet
Article
Biochemistry & Molecular Biology
Fanny Seraphine Krebs, Bianca Moura, Edoardo Missiaglia, Veronica Aedo-Lopez, Olivier Michielin, Petros Tsantoulis, Bettina Bisig, Mounir Trimech, Vincent Zoete, Krisztian Homicsko
Summary: The development of targeted therapies for non-BRAF p.Val600-mutant melanomas remains challenging as Triple wildtype (TWT) melanomas lacking BRAF, NRAS, or NF1 mutations are heterogeneous in their genomic drivers. MAP2K1 mutations are enriched in BRAF-mutant melanomas and function as resistance mechanisms to BRAF inhibition. This case study illustrates the difficulties in combining MEK1 and CDK4/6 inhibitors in the presence of resistance to MEK inhibitor monotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Anna Reka Percze, Alexandra Nagy, Lorinc Polivka, Eniko Barczi, Ibolya Czaller, Zsuzsanna Kovats, Janos Tamas Varga, Judit H. Ballai, Veronika Muller, Gabor Horvath
Summary: A study on SARS-CoV-2 variants of concerns found differences in long-term sequelae and emphasized the importance of managing fatigue and sleep disturbances in long COVID patient care.
INFLAMMOPHARMACOLOGY
(2023)
Article
Oncology
Xinyue Dong, Jun Ren, Zohreh Amoozgar, Somin Lee, Meenal Datta, Sylvie Roberge, Mark Duquette, Dai Fukumura, Rakesh K. Jain
Summary: Chimeric antigen receptor (CAR)-T cells have limited efficacy in treating glioblastoma (GBM) and other solid tumors due to the immunosuppressive tumor microenvironment (TME). Previous studies have shown that blocking vascular endothelial growth factor (VEGF) signaling can improve tumor vessel normalization and enhance the delivery of CD8+ T cells for effective immunotherapy. In this study, the researchers tested the hypothesis that anti-VEGF therapy can improve the delivery and efficacy of CAR-T cells in mice with GBM tumors, and found that it indeed enhanced CAR-T cell infiltration, delayed tumor growth, and prolonged survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Alexandre Wicky, Roberto Gatta, Sofiya Latifyan, Rita De Micheli, Camille Gerard, Sylvain Pradervand, Olivier Michielin, Michel A. Cuendet
Summary: The increasing availability of clinical real-world data (RWD) provides an opportunity to supplement evidence from randomized clinical trials and explore treatment outcomes in real-life conditions. Process mining is a suitable methodology for analyzing treatment paths and outcomes. In this study, an interactive application was implemented to compare treatment sequences based on overall survival, progression-free survival, and best overall response. The application was used to conduct a descriptive analysis of RWD in advanced melanoma patients and explore the outcomes of different treatment choices. Results showed long-term survival benefits from immune-checkpoint inhibitors rechallenge, suggesting potential implications for treatment guidelines.
FRONTIERS IN ONCOLOGY
(2023)
Article
Sport Sciences
Mira Ambrus, Eszter Fodor, Timea Berki, Veronika Muller, Adam Uhlar, Istvan Hornyak, Zsombor Lacza
Summary: Professional athletes are at high risk of COVID-19 infection but do not develop long-term immunity through neutralizing immunoglobulins. Elevated markers of cellular and secretory immunity indicate that these systems may be responsible for virus elimination in this subpopulation.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)